SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Daniel Acker — Bloomberg via Getty Images

57

Pfizer

PFE

Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company is now mulling whether to sell its consumer healthcare business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.

Looking for leads, investment insights, or competitive intelligence?

CEO

Ian C. Read

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York City

Years on Fortune 500 List

24

Employees

90,200

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$52,546-0.5%
Profits ($M)$21,308.0195.3%
Assets ($M)$171,797
Total Stockholder Equity ($M)$71,308
Market Value — as of March 29, 2018 ($M)$211,115
Profit Ratios
Profit as % of Revenues40.6%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity29.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.52
EPS % Change (from 2016)200.9%
EPS % Change (5 year annual rate)12.7%
EPS % Change (10 year annual rate)11.6%
Total Return
Total Return to Investors (2017)15.7%
Total Return to Investors (5 year, annualized)11.4%
Total Return to Investors (10 year, annualized)9.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

Russian Drugmaker Granted License to Produce Celgene Copycat

Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.

Read More →
3 Key Lessons From Trump's Drug Price Feud With Pfizer

Pfizer temporarily backed down on price hikes following Trump's threats.

Read More →